Gonadorelin, Research Overview & Evidence

Overview

Synthetic GnRH, approved for diagnostic use and widely used off-label to maintain endogenous testicular function.

Gonadorelin is classified as a gonadotropin-releasing hormone. Its current development status is: approved (diagnostic use). Multiple randomised controlled trials in humans support the primary claims made for this compound.

The Peptide Institute tracks Gonadorelin because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.

Independent Testing

Independently tested companies that sell Gonadorelin

Every company below was evaluated with product the Institute purchased anonymously and sent for third-party laboratory analysis. Ranked by Index Score™.

Companies: 3
Samples: 5
Updated: Jan 26, 2026

1 Apex Peptides Exceptional Institute
Top Rated Gonadorelin
98.4% average purity across 1 sample
Purity & Testing 99 Transparency 90 Samples 1 91 View company
2 Halcyon Biosciences Excellent
99% average purity across 2 samples
Purity & Testing 99 Transparency 90 Samples 2 89 View company
3 NextGen Peptides Excellent
1 quantity discrepancy across 2 samples
Purity & Testing 91 Transparency 80 Samples 2 85 View company

Compare all tested Gonadorelin companies

Research & Studies

Studies library

Comparative effects of Gonadorelin on metabolic endpoints

The Lancet Diabetes & Endocrinology · Randomized controlled trial (Phase 2) · Mar 21, 2024

Adds to the Gonadorelin evidence base without resolving the central question of human efficacy.
Gonadorelin in preclinical models: efficacy and translational limits

Frontiers in Pharmacology · Randomized controlled trial (Phase 2) · Apr 28, 2022

One of the more methodologically careful entries in the Gonadorelin literature.
Immunogenicity and stability profile of Gonadorelin

Journal of Controlled Release · Open-label extension study · Jan 25, 2017

One of the more methodologically careful entries in the Gonadorelin literature.